Merck Begins Two Phase 3 Studies Of Pneumococcal Disease Vaccine PCV-15 (V114)

Merck & Co. Inc. (MRK) said it is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.

from RTT - Biotech https://ift.tt/2IZJlaP
via IFTTT